Fe3O4@ Pt nanozymes combining with CXCR4 antagonists to synergistically treat acute myeloid leukemia

References

ref title DOI material type comment
4178 992 Fe3O4@ Pt nanozymes combining with CXCR4 antagonists to synergistically treat acute myeloid leukemia https://doi.org/10.1016/j.nantod.2021.101106 Composite To overcome these problems, a multifunctional nanoplatform of Fe3O4@Pt composite nanozyme conjugating CXCR4 antagonist was designed, aiming to synergistically treat AML for the first time, in which, the CXCR4 antagonist was used to specifically target AML cells as well as to significantly interfere CXCR4/CXCL12 axis. In the mildly acidic lysosome microenvironment, highly toxic reactive oxygen species (ROS) was generated through the sequential catalytic reactions of Fe3O4@Pt to trigger AML cells apoptosis, leaving the normal cells unharmed.

Materials

ref material size size err size unit size type size comment BET b nanozyme b 10n b unit specific act sa 10n sa unit comment

Kinetics

ref material enzyme type substrate pH T km km err km 10n km unit vmax vmax err vmax 10n vmax unit kcat kcat err kcat 10n kcat unit kcat/km kcat/km 10n kcat/km unit comment
6906 992 Fe3O4@PEG POD H2O2 2-11 20-80 22.59 mM 0.028 -6 M/s 992
6901 992 Fe3O4@PEG POD H2O2 13.768 mM 29.06 -8 M/s 992

Applications

ref material application target method linear range linear ran unit LOD lod unit recovery comment
5899 992 Fe3O4@Pt@E5 AML treatment